Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Yu. A. Danilogorskaya"'
Autor:
V. V. Arkhipov, T. S. Kheilo, E. G. Gladysheva, Yu. A. Danilogorskaya, M. R. Dzhavatkhanova, S. V. Snytko, I. V. Samorukova, M. V. Zhuravleva
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 1, Pp 78-90 (2022)
Microcirculation dysfunction plays a significant role in the development of post-COVID syndrome caused by SARS-CoV-2. However, there have been no studies on changes in microcirculation parameters during pharmacotherapy in patients with post-COVID syn
Externí odkaz:
https://doaj.org/article/2d765c71b5524fb2891729b3587b230b
Autor:
A. A. Shchendrygina, K. A. Zhbanov, E. V. Privalova, A. O. Yusupova, Yu. A. Danilogorskaya, E. Yu. Salakheeva, I. Ya. Sokolova, S. A. Tsatsurova, A. A. Ageeva, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 3, Pp 476-483 (2021)
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is
Externí odkaz:
https://doaj.org/article/c7ce94c4d13c4fb0b9597a86d8501960
Autor:
Yu. A. Danilogorskaya, E. A. Zheleznykh, E. A. Privalova, Yu. N. Belenkov, A. A. Shchendrigina, M. V. Kozhevnikova, G. A. Shakaryants, V. Y. Zektser, A. S. Lishuta, I. S. Ilgisonis
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 15, Iss 3, Pp 328-334 (2019)
Aim. To study some vascular remodeling markers in hypertensive patients depending on the presence of type 2 diabetes mellitus.Material and methods. The study included patients with essential hypertension 1-2 degrees of increase in blood pressure with
Externí odkaz:
https://doaj.org/article/8599c7d6eda940c19466709b6e680653
Autor:
Yu. A. Danilogorskaya, E. A. Zheleznykh, E. V. Privalova, A. A. Shchendrygina, Yu. N. Belenkov, I. S. Ilgisonis, M. I. Tishman
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 12, Pp 113-119 (2017)
Aim. Recently, the problem of endothelial dysfunction is in high interest. It was proved that microcirculatory disorders play main role in development and progression of target organ damage in essential arterial hypertension (EAH). Microcirculatory b
Externí odkaz:
https://doaj.org/article/42e184cdb8f9424eb92a06639796671e
Autor:
Yu. N. Belenkov, E. V. Privalova, E. A. Zheleznykh, Yu. A. Danilogorskaya, I. S. Chekneva, O. A. Azizova, A. V. Aseychev, A. G. Shvachko
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 2, Pp 52-58 (2010)
Externí odkaz:
https://doaj.org/article/4cde8dcba680463ca5e734fec04f4145
Autor:
Yu. N. Belenkov, E. V. Privalova, Yu. A. Danilogorskaya, E. A. Zheleznykh, A. A. Shchendrygina
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 3, Pp 85-87 (2012)
Risk factors are the cornerstone of the cardiovascular continuum concept. Arterial hypertension is one of major risk factors, which accounts for a substantial proportion of cardiovascular morbidity and mortality due to cardiovascular complications (C
Externí odkaz:
https://doaj.org/article/de8529cf79be4e609b3106fc803f6383
Autor:
Ju. I. Safonova, M. V. Kozhevnikova, Yu. A. Danilogorskaya, E. A. Zheleznykh, I. S. Ilgisonis, E. V. Privalova, N. V. Khabarova, Yu. N. Belenkov
Publikováno v:
Kardiologiia. 62:65-71
Aim To evaluate the effect of perindopril on the endothelial function and levels of endothelial dysfunction markers in groups of patients with heart failure with preserved (HFpEF) and mid-range (intermediate) left ventricular ejection fraction (HFmrE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd61ca35499e8f17bbb68e066c8e986
https://doi.org/10.18087/cardio.2022.1.n1952
https://doi.org/10.18087/cardio.2022.1.n1952
Autor:
E. A. Privalova, Yu. N. Belenkov, Yu. A. Danilogorskaya, E. A. Zheleznykh, M. V. Kozhevnikova, V. Y. Zektser, A. S. Lishuta, I. S. Ilgisonis
Publikováno v:
Kardiologiia. 62:24-31
Aim To study the dynamics of serum markers for vascular remodeling in patients with arterial hypertension (AH), including AH associated with type 2 diabetes mellitus (DM2) during the 12-month treatment with the angiotensin-converting enzyme (ACE) inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac485044d55ba5e2f414c4db7334631
https://doi.org/10.18087/cardio.2022.1.n1890
https://doi.org/10.18087/cardio.2022.1.n1890
Autor:
Yu A Danilogorskaya, Yu N Belenkov, I. Ya. Sokolova, E. Yu. Salakheeva, S. A. Tsatsurova, A A Shchendrygina, A. A. Ageeva, K. A. Zhbanov, E. V. Privalova, A. O. Yusupova
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 3, Pp 476-483 (2021)
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a437227612ae7820537df786f1db790b
https://doi.org/10.20996/1819-6446-2021-05-01
https://doi.org/10.20996/1819-6446-2021-05-01
Autor:
J. I. Safonova, M. V. Kozhevnikova, Yu. A. Danilogorskaya, E. A. Zheleznykh, V. Y. Zektser, A. A. Shchendrygina, I. S. Ilgisonis, E. V. P., N. V. Khabarova, Yu. N. Belenkov
Publikováno v:
Kardiologiia. 60:65-70
Aim To evaluate the effect of 12-month perindopril treatment on structure and function of microvasculature (MV) in patients with chronic heart failure with preserved (HFpEF) and intermediate (HFiEF) left ventricular ejection fraction.Material and met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d9287d4c84fd71a0fe96eab91a0018
https://doi.org/10.18087/cardio.2020.8.n1216
https://doi.org/10.18087/cardio.2020.8.n1216